shadow_tr

 

 

Inventor

   David H. Coy, Ph.D.

 

Intellectual Property

   U.S. Patent No. 7,771,727

 

 

Available for

  • Exclusive Licensing in a Field
  • Non-exclusive Licensing
  • Scientific Collaboration

 

 

Confidential Disclosure Agreement

 

 

For more information, please contact:

     Jenna Matheny
     Licensing Associate
     504-988-6962
     jmatheny@tulane.edu

 

Conjugates of Therapeutic or Cytotoxic Agents and Biologically Active Peptides (printable)

 

Tulane University is actively seeking commercial entities to further develop and commercialize a novel prodrug design which conjugates a therapeutic or cytotoxic agent and a targeting moiety via carbamate linkage.

 

 

Applications

  • Targeted, cell-specific method for delivering therapeutic or cytotoxic agents to cells when internalized by those cells which possess a receptor specific to the carbamate bound ligand
  • Method for treatment of cancers of certain cancers in which the cancerous cells express tumor-cell specific receptors


 

Advantages

  • Unique, cell-type specific method for delivery of therapeutic agents
  • Reduces the incidence of cytotoxicity during chemotherapy
  • Simple to produce
  • Predictable mode of action



Development Status

This technology has been tested extensively in vitro. Laboratory work is ongoing and a patent has been issued.

 


 

Related Publications

Tulane University, New Orleans, LA 70118 504-865-5000 website@tulane.edu